Extrahepatic Radioembolization: New Frontiers Beyond the Liver

To review current concepts regarding the application of extrahepatic yttrium-90 radioembolization.



Background:

Ytrrium-90 transarterial radioembolization (TARE) has been established as a locoregional therapy for intermediate and advanced hepatocellular carcinoma{1}. TARE is typically reserved for primary and secondary liver neoplasms, but recent studies have reported use of radioembolization applied to extrahepatic sites (e.g., colorectal, prostate, brain){2–7}. Although many investigations have been limited to primarily animal models{6,7}, growing interests in expanding the role of TARE marks potential for new indications using this treatment strategy.


Clinical Findings/Procedure Details: This educational exhibit will: (1) present an overview of current indications and procedure approaches for TARE, (2) review studies using extrahepatic radioembolization beyond conventional use, (3) present a case-based review of extrahepatic applications of TARE including treatments of the prostate, colon, spleen, and brain, (4) highlight treatment outcomes, along with limitations and pertinent contraindications, and (5) discuss future directions and current gaps in the literature.

Conclusion and/or Teaching Points: After reviewing this exhibit, the viewer will develop a deeper understanding of the technical components and advantages of using TARE with a focus on its potential utility among extrahepatic disease-states.